- Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
- Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
- Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
- Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
- Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
- Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
- New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
- Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
- Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
- Natera to Participate in March Investor Conferences
More ▼
Key statistics
As of last trade Natera Inc (NTRA:NSQ) traded at 92.32, -6.58% below its 52-week high of 98.82, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 92.00 |
---|---|
High | 92.33 |
Low | 91.05 |
Bid | 92.22 |
Offer | 92.37 |
Previous close | 91.28 |
Average volume | 1.22m |
---|---|
Shares outstanding | 122.24m |
Free float | 115.03m |
P/E (TTM) | -- |
Market cap | 11.16bn USD |
EPS (TTM) | -3.80 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 16:52 BST.
More ▼